KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Efficacy and safety of sacubitril/valsartan in Afro-descendant patients with resistant hypertension: a randomized controlled trial.

Yasmin de Souza Lima Bitar, André Rodrigues Durães, Cristiano Ricardo Bastos de Macedo, Marcela Gordilho Aras, Levi Cardozo Santos, Rogério Smith Freire de Abreu, Enilson Carmo Barbosa Dos Santos, Edimar Bocchi, Wallace Andre Pedro da Silva, Roque Aras Junior

J Hypertens 43(9) 1485-1491

PMID40621831
PMCID-
DOI10.1097/HJH.0000000000004075
发表日期2025-07-07
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Sacubitril/valsartan (Sac-Val) has demonstrated blood pressure (BP)-lowering effects, but its role in resistant hypertension remains unclear. This study evaluated the efficacy and safety of Sac-Val compared to optimized angiotensin II receptor blocker (ARB) or angiotensin-converting enzyme inhibitor (ACEI) therapy in Brazilian patients with resistant hypertension, predominantly Afro-descendant. METHODS: In this phase III, 8-week, single-center, randomized trial, 80 adults with resistant hypertension were assigned to Sac-Val (titrated to 200 mg with an optional increase to 400 mg if BP remained >140/90 mmHg) or standard therapy (ARB/ACEI combined with other antihypertensive agents). The primary endpoint was the proportion of patients achieving BP control (<140/90 mmHg). The co-primary endpoints included mean reductions in mean sitting SBP (msSBP), mean sitting DBP (msDBP), and mean sitting pulse pressure (msPP) at week 8. Secondary outcomes assessed dose-dependent BP reduction. RESULTS: BP control was achieved in 94.9% of patients in the Sac-Val group versus 69.2% in the control group ( P = 0.03). Sac-Val significantly reduced msPP (-6.05 mmHg, P = 0.008) and showed a trend toward greater msSBP reduction ( P = 0.06). The 400 mg dose resulted in the greatest BP reduction, particularly for msPP ( P = 0.034). No deaths were reported. CONCLUSION: Sac-Val was more effective than standard therapy in achieving BP control and reducing BP in resistant hypertension, with a dose-dependent trend favoring the 400 mg regimen. These findings support Sac-Val as a potential treatment alternative for high-risk Afro-descendant patients.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。